^
    11d
    Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (clinicaltrials.gov)
    P=N/A, N=101, Completed, University of Chicago | Trial primary completion date: Dec 2027 --> Apr 2025 | Recruiting --> Completed | Trial completion date: Dec 2027 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    13d
    Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    14d
    Case Report: Successful natural conception and delivery in a primary cancer survivor involving the reproductive, respiratory, and endocrine systems auth. (PubMed, Front Oncol)
    She received six cycles of postoperative leuprorelin therapy...The polyp was resected, and the patient received a 14-day course of anti-infective therapy with metronidazole and levofloxacin, after which she was guided by natural conception...It establishes an MDT management pathway encompassing "determination of oncologic remission status, intervention for reversible fertility-compromising factors, and cross-trimester monitoring." This confirms that natural pregnancy is safe and feasible for patients in cancer remission, with multi-disciplinary collaboration and rigorous monitoring. The absence of postpartum neoplasm recurrence and abnormalities in offspring provides a practical paradigm for fertility management in patients with MPNs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    leuprolide acetate for depot suspension
    19d
    HYP-OP-RT: Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (clinicaltrials.gov)
    P=N/A, N=434, Not yet recruiting, CHU de Quebec-Universite Laval
    New trial • Head-to-Head
    |
    goserelin acetate
    19d
    The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles (clinicaltrials.gov)
    P4, N=600, Completed, Cairo University | Recruiting --> Completed
    Trial completion
    21d
    RADVAN: Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (clinicaltrials.gov)
    P3, N=374, Active, not recruiting, Sun Yat-sen University
    New P3 trial
    |
    triptorelin • goserelin acetate
    25d
    RATIONAL-PCS: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (clinicaltrials.gov)
    P2, N=162, Recruiting, Ontario Clinical Oncology Group (OCOG) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eligard (leuprolide acetate)
    28d
    Retrospective analysis of growth hormone effects on growth and adenoma volume in children with pituitary microadenoma. (PubMed, Transl Pediatr)
    Female and male subgroups differed significantly in PAH and BA-CA improvements (P<0.05). Combined GH and leuprorelin enhances linear growth and delayed bone maturation in children with PM and compromised PAH, without promoting tumor growth or sustained IGF-1 elevation.
    Retrospective data • Journal
    |
    IGF1 (Insulin-like growth factor 1)
    |
    leuprolide acetate for depot suspension
    28d
    Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    HR positive
    |
    goserelin acetate
    28d
    PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=130, Not yet recruiting, CancerCare Manitoba
    New trial
    |
    goserelin acetate
    1m
    Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, University of Chicago | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    1m
    Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. (PubMed, Case Rep Oncol Med)
    A 75-year-old man with mHSPC was treated with Apa and leuprorelin. Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    apalutamide • cyclosporine • leuprolide acetate for depot suspension